Capital Management Corp VA Has $5.36 Million Stock Holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK)

Capital Management Corp VA raised its stake in Anika Therapeutics, Inc. (NASDAQ:ANIK - Free Report) by 12.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 325,545 shares of the biotechnology company's stock after buying an additional 35,195 shares during the period. Capital Management Corp VA owned approximately 2.22% of Anika Therapeutics worth $5,358,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Meros Investment Management LP grew its holdings in shares of Anika Therapeutics by 11.6% in the 3rd quarter. Meros Investment Management LP now owns 237,295 shares of the biotechnology company's stock worth $5,861,000 after acquiring an additional 24,581 shares during the last quarter. Stonepine Capital Management LLC increased its stake in Anika Therapeutics by 14.5% in the 3rd quarter. Stonepine Capital Management LLC now owns 189,308 shares of the biotechnology company's stock worth $4,676,000 after purchasing an additional 23,911 shares in the last quarter. Segall Bryant & Hamill LLC raised its holdings in Anika Therapeutics by 1.7% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 108,799 shares of the biotechnology company's stock worth $2,687,000 after buying an additional 1,794 shares during the period. Bank of New York Mellon Corp raised its holdings in Anika Therapeutics by 20.8% during the 4th quarter. Bank of New York Mellon Corp now owns 50,529 shares of the biotechnology company's stock worth $832,000 after buying an additional 8,711 shares during the period. Finally, Barclays PLC lifted its stake in Anika Therapeutics by 66.6% during the third quarter. Barclays PLC now owns 32,664 shares of the biotechnology company's stock valued at $806,000 after buying an additional 13,054 shares in the last quarter. Institutional investors and hedge funds own 91.53% of the company's stock.

Remove Ads

Anika Therapeutics Stock Up 1.9 %

Shares of Anika Therapeutics stock traded up $0.32 during trading on Wednesday, hitting $17.11. The stock had a trading volume of 113,871 shares, compared to its average volume of 68,236. The company has a market capitalization of $250.59 million, a PE ratio of -2.57 and a beta of 0.95. Anika Therapeutics, Inc. has a 1 year low of $15.40 and a 1 year high of $29.11. The stock has a 50 day simple moving average of $16.91 and a 200 day simple moving average of $19.66.

Anika Therapeutics (NASDAQ:ANIK - Get Free Report) last released its earnings results on Wednesday, March 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.13). Anika Therapeutics had a negative net margin of 59.40% and a negative return on equity of 2.22%. As a group, equities analysts expect that Anika Therapeutics, Inc. will post -0.84 earnings per share for the current fiscal year.

Anika Therapeutics Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.